<p>BioCryst 制药（NASDAQ:BCRX - 获取免费报告）在周一发布的研究报告中，HC Wainwright 将其目标价格从 30.00 美元上调至 32.00 美元，Benzinga 报道。该公司目前对这家生物技术公司的股票给予 “买入” 评级。HC Wainwright 的目标价格暗示该公司股价有 321.33% 的潜在上涨空间。</p>
<p>其他几位研究分析师也最近对 BCRX 发表了评论。Evercore ISI 在 10 月 1 日的报告中重申了 “持平” 评级，并对 BioCryst 制药的股票设定了 8.00 美元的目标价格。Needham &amp; Company LLC 在 11 月 4 日的研究报告中将 BioCryst 制药的目标价格从 20.00 美元下调至 18.00 美元，并对该公司给予 “买入” 评级。Cantor Fitzgerald 在 10 月 15 日的报告中将 BioCryst 制药的目标价格从 24.00 美元上调至 26.00 美元，并给予该公司 “增持” 评级。Weiss Ratings 在 12 月 2 日的研究报告中重申了对 BioCryst 制药的 “卖出（e+）” 评级。最后，Citizens Jmp 在 11 月 5 日的研究报告中将 BioCryst 制药的目标价格从 27.00 美元下调至 25.00 美元，并对该股票给予 “市场表现优于大盘” 评级。十位分析师对该股票给予了买入评级，三位给予了持平评级，一位给予了卖出评级。根据 MarketBeat 的数据，BioCryst 制药目前的平均评级为 “适度买入”，共识目标价格为 19.50 美元。</p>
<p><strong>获取我们关于 BioCryst 制药的最新股票报告</strong></p>
<h2>BioCryst 制药股票表现</h2>
<p>周一中午交易时，BCRX 股票上涨 0.03 美元，达到 7.60 美元。该股票交易量为 1,874,402 股，而其平均交易量为 4,014,464 股。该公司的 50 日简单移动平均线为 7.15 美元，200 日简单移动平均线为 8.22 美元。该公司的市值为 16 亿美元，市盈率为-152.06，贝塔值为 0.91。BioCryst 制药的 12 个月低点为 6.00 美元，12 个月高点为 11.31 美元。</p>
<p>BioCryst 制药（NASDAQ:BCRX - 获取免费报告）在 11 月 3 日发布了其季度财报。这家生物技术公司报告本季度每股收益为 0.06 美元，低于共识预期的 0.07 美元（差额为 0.01 美元）。BioCryst 制药的股本回报率为-4.24%，净利润率为-1.46%。该公司本季度的收入为 1.594 亿美元，而共识预期为 1.6291 亿美元。去年同期，该公司每股收益为-0.07 美元。与去年同期相比，BioCryst 制药的收入增长了 36.1%。分析师预测 BioCryst 制药在当前年度的每股收益将为-0.36 美元。</p>
<h2>内部买卖</h2>
<p>在相关消息中，内部人士 Alane P. Barnes 在 12 月 3 日的交易中出售了 19,770 股公司的股票。该股票以平均价格 7.65 美元出售，总价值为 151,240.50 美元。出售完成后，该内部人士持有 345,476 股公司股票，价值约为 2,642,891.40 美元。这代表其持股比例减少了 5.41%。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。在过去三个月中，内部人士共出售了价值 1,164,401 美元的 161,680 股公司股票。目前，内部人士持有该股票的比例为 5.10%。</p>
<h2>机构资金流入和流出</h2>
<p>一些机构投资者最近买入和卖出了该股票的股份。Deerfield Management Company L.P.在第三季度将其在 BioCryst 制药的股份增加了 159.4%。Deerfield Management Company L.P.目前拥有 12,169,000 股该生物技术公司的股票，价值 92,363,000 美元，此前在上个季度又购买了 7,477,000 股。Arrowstreet Capital Limited Partnership 在第二季度将其在 BioCryst 制药的持股增加了 2,103.7%。Arrowstreet Capital Limited Partnership 目前拥有 4,278,555 股该生物技术公司的股票，价值 38,336,000 美元，此前在上个季度又收购了 4,084,403 股。Assenagon Asset Management S.A.在第二季度将其在 BioCryst 制药的股份增加了 25,631.2%。Assenagon Asset Management S.A.目前拥有 3,620,637 股该生物技术公司的股票，价值 32,441,000 美元，此前在上个季度又收购了 3,606,566 股。Millennium Management LLC 在第一季度将其在 BioCryst 制药的股份增加了 382.6%。Millennium Management LLC 目前拥有 3,812,874 股该生物技术公司的股票，价值 28,597,000 美元，此前在上个季度又购买了 3,022,769 股。最后，Qube Research &amp; Technologies Ltd 在第二季度将其在 BioCryst 制药的持股增加了 152.3%。Qube Research &amp; Technologies Ltd 目前拥有 2,373,489 股该生物技术公司的股票，价值 21,266,000 美元，此前在上个季度又购买了 1,432,824 股。机构投资者目前持有该公司 85.88% 的股票。</p>
<h2>关于 BioCryst 制药</h2>
<p>（获取免费报告）</p>
<p>BioCryst 制药公司是一家生物技术公司，开发口服小分子和蛋白质治疗药物以治疗罕见疾病。该公司市场上销售的药物包括用于治疗急性非复杂流感的静脉注射神经氨酸酶抑制剂 peramivir，品牌名为 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及用于治疗遗传性血管性水肿的口服丝氨酸蛋白酶抑制剂 ORLADEYO。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 BioCryst Pharmaceuticals</li>
<li>投资汽车股票</li>
<li>超级微型公司的抛售是海市蜃楼——以下是为什么反弹可能会迅速回归的原因</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>3 家公司将大现金流转化为更大的股东收益</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>GOOGL 的不可阻挡的势头将价格目标推至历史新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 BioCryst Pharmaceuticals 吗？</h2>
<p>在考虑 BioCryst Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 BioCryst Pharmaceuticals 并不在名单上。</p>
<p>虽然 BioCryst Pharmaceuticals 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BioCryst制药

<p>HC Wainwright 将 BioCryst Pharmaceuticals 的目标价格从 30 美元上调至 32 美元，维持 “买入” 评级，暗示潜在上涨幅度为 321.33%。其他分析师的评级各不相同，平均共识为 “适度买入”，目标价为 19.50 美元。BioCryst 的股票表现略有上升，内部人士和机构活动有所记录。尽管未能达到每股收益预期，该公司报告的收入同比增长 36.1%</p>

<p>BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its target price lifted by research analysts at HC Wainwright from $30.00 to $32.00 in a research report issued on Monday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the biotechnology company's stock. HC Wainwright's price target suggests a potential upside of 321.33% from the company's previous close.</p>
<div class="lb-trans"><p>BioCryst 制药（NASDAQ:BCRX - 获取免费报告）在周一发布的研究报告中，HC Wainwright 将其目标价格从 30.00 美元上调至 32.00 美元，Benzinga 报道。该公司目前对这家生物技术公司的股票给予 “买入” 评级。HC Wainwright 的目标价格暗示该公司股价有 321.33% 的潜在上涨空间。</p>
</div><p>Several other research analysts have also recently commented on BCRX. Evercore ISI reiterated an &#34;in-line&#34; rating and issued a $8.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Needham &amp; Company LLC reduced their price objective on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a &#34;buy&#34; rating for the company in a research note on Tuesday, November 4th. Cantor Fitzgerald increased their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, October 15th. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, December 2nd. Finally, Citizens Jmp decreased their target price on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a &#34;market outperform&#34; rating on the stock in a research report on Wednesday, November 5th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BioCryst Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $19.50.</p>
<div class="lb-trans"><p>其他几位研究分析师也最近对 BCRX 发表了评论。Evercore ISI 在 10 月 1 日的报告中重申了 “持平” 评级，并对 BioCryst 制药的股票设定了 8.00 美元的目标价格。Needham &amp; Company LLC 在 11 月 4 日的研究报告中将 BioCryst 制药的目标价格从 20.00 美元下调至 18.00 美元，并对该公司给予 “买入” 评级。Cantor Fitzgerald 在 10 月 15 日的报告中将 BioCryst 制药的目标价格从 24.00 美元上调至 26.00 美元，并给予该公司 “增持” 评级。Weiss Ratings 在 12 月 2 日的研究报告中重申了对 BioCryst 制药的 “卖出（e+）” 评级。最后，Citizens Jmp 在 11 月 5 日的研究报告中将 BioCryst 制药的目标价格从 27.00 美元下调至 25.00 美元，并对该股票给予 “市场表现优于大盘” 评级。十位分析师对该股票给予了买入评级，三位给予了持平评级，一位给予了卖出评级。根据 MarketBeat 的数据，BioCryst 制药目前的平均评级为 “适度买入”，共识目标价格为 19.50 美元。</p>
</div><p><strong>Get Our Latest Stock Report on BioCryst Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 BioCryst 制药的最新股票报告</strong></p>
</div><h2>BioCryst Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>BioCryst 制药股票表现</h2>
</div><p>Shares of BCRX stock traded up $0.03 during mid-day trading on Monday, hitting $7.60. 1,874,402 shares of the stock traded hands, compared to its average volume of 4,014,464. The company's 50-day simple moving average is $7.15 and its 200-day simple moving average is $8.22. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -152.06 and a beta of 0.91. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.31.</p>
<div class="lb-trans"><p>周一中午交易时，BCRX 股票上涨 0.03 美元，达到 7.60 美元。该股票交易量为 1,874,402 股，而其平均交易量为 4,014,464 股。该公司的 50 日简单移动平均线为 7.15 美元，200 日简单移动平均线为 8.22 美元。该公司的市值为 16 亿美元，市盈率为-152.06，贝塔值为 0.91。BioCryst 制药的 12 个月低点为 6.00 美元，12 个月高点为 11.31 美元。</p>
</div><p>BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The business had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. During the same quarter last year, the firm posted ($0.07) earnings per share. BioCryst Pharmaceuticals's revenue was up 36.1% compared to the same quarter last year. Analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>BioCryst 制药（NASDAQ:BCRX - 获取免费报告）在 11 月 3 日发布了其季度财报。这家生物技术公司报告本季度每股收益为 0.06 美元，低于共识预期的 0.07 美元（差额为 0.01 美元）。BioCryst 制药的股本回报率为-4.24%，净利润率为-1.46%。该公司本季度的收入为 1.594 亿美元，而共识预期为 1.6291 亿美元。去年同期，该公司每股收益为-0.07 美元。与去年同期相比，BioCryst 制药的收入增长了 36.1%。分析师预测 BioCryst 制药在当前年度的每股收益将为-0.36 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, insider Alane P. Barnes sold 19,770 shares of the company's stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $7.65, for a total value of $151,240.50. Following the completion of the sale, the insider owned 345,476 shares in the company, valued at approximately $2,642,891.40. This represents a 5.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 161,680 shares of company stock worth $1,164,401. 5.10% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Alane P. Barnes 在 12 月 3 日的交易中出售了 19,770 股公司的股票。该股票以平均价格 7.65 美元出售，总价值为 151,240.50 美元。出售完成后，该内部人士持有 345,476 股公司股票，价值约为 2,642,891.40 美元。这代表其持股比例减少了 5.41%。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。在过去三个月中，内部人士共出售了价值 1,164,401 美元的 161,680 股公司股票。目前，内部人士持有该股票的比例为 5.10%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors have recently bought and sold shares of the stock. Deerfield Management Company L.P. raised its stake in shares of BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company's stock worth $92,363,000 after purchasing an additional 7,477,000 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in BioCryst Pharmaceuticals by 2,103.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company's stock valued at $38,336,000 after acquiring an additional 4,084,403 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of BioCryst Pharmaceuticals by 25,631.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company's stock worth $32,441,000 after acquiring an additional 3,606,566 shares in the last quarter. Millennium Management LLC boosted its stake in BioCryst Pharmaceuticals by 382.6% in the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock valued at $28,597,000 after buying an additional 3,022,769 shares in the last quarter. Finally, Qube Research &amp; Technologies Ltd grew its holdings in shares of BioCryst Pharmaceuticals by 152.3% during the 2nd quarter. Qube Research &amp; Technologies Ltd now owns 2,373,489 shares of the biotechnology company's stock valued at $21,266,000 after purchasing an additional 1,432,824 shares during the last quarter. Institutional investors own 85.88% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者最近买入和卖出了该股票的股份。Deerfield Management Company L.P.在第三季度将其在 BioCryst 制药的股份增加了 159.4%。Deerfield Management Company L.P.目前拥有 12,169,000 股该生物技术公司的股票，价值 92,363,000 美元，此前在上个季度又购买了 7,477,000 股。Arrowstreet Capital Limited Partnership 在第二季度将其在 BioCryst 制药的持股增加了 2,103.7%。Arrowstreet Capital Limited Partnership 目前拥有 4,278,555 股该生物技术公司的股票，价值 38,336,000 美元，此前在上个季度又收购了 4,084,403 股。Assenagon Asset Management S.A.在第二季度将其在 BioCryst 制药的股份增加了 25,631.2%。Assenagon Asset Management S.A.目前拥有 3,620,637 股该生物技术公司的股票，价值 32,441,000 美元，此前在上个季度又收购了 3,606,566 股。Millennium Management LLC 在第一季度将其在 BioCryst 制药的股份增加了 382.6%。Millennium Management LLC 目前拥有 3,812,874 股该生物技术公司的股票，价值 28,597,000 美元，此前在上个季度又购买了 3,022,769 股。最后，Qube Research &amp; Technologies Ltd 在第二季度将其在 BioCryst 制药的持股增加了 152.3%。Qube Research &amp; Technologies Ltd 目前拥有 2,373,489 股该生物技术公司的股票，价值 21,266,000 美元，此前在上个季度又购买了 1,432,824 股。机构投资者目前持有该公司 85.88% 的股票。</p>
</div><h2>About BioCryst Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 BioCryst 制药</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.</p>
<div class="lb-trans"><p>BioCryst 制药公司是一家生物技术公司，开发口服小分子和蛋白质治疗药物以治疗罕见疾病。该公司市场上销售的药物包括用于治疗急性非复杂流感的静脉注射神经氨酸酶抑制剂 peramivir，品牌名为 RAPIVAB、RAPIACTA 和 PERAMIFLU；以及用于治疗遗传性血管性水肿的口服丝氨酸蛋白酶抑制剂 ORLADEYO。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than BioCryst Pharmaceuticals</li>
<li>Investing In Automotive Stocks</li>
<li>Super Micro's Sell-Off Is a Mirage—Here’s Why the Rally May Come Back Fast</li>
<li>Canada Bond Market Holiday: How to Invest and Trade</li>
<li>3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>GOOGL's Unstoppable Momentum Drives Price Targets to Record Highs</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 BioCryst Pharmaceuticals</li>
<li>投资汽车股票</li>
<li>超级微型公司的抛售是海市蜃楼——以下是为什么反弹可能会迅速回归的原因</li>
<li>加拿大债券市场假期：如何投资和交易</li>
<li>3 家公司将大现金流转化为更大的股东收益</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>GOOGL 的不可阻挡的势头将价格目标推至历史新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNSWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 BioCryst Pharmaceuticals 吗？</h2>
</div><p>Before you consider BioCryst Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 BioCryst Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 BioCryst Pharmaceuticals 并不在名单上。</p>
</div><p>While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 BioCryst Pharmaceuticals 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 预测 BioCryst 制药（NASDAQ:BCRX）股票将出现强劲的价格升值